Martin Filipits

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 159 publications

The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer.

The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer.

Journal: Clinical breast cancer

Published: April 01, 2026

High-grade serous ovarian cancer is associated with increased TP53 mutation burden in uterine lavage.

High-grade serous ovarian cancer is associated with increased TP53 mutation burden in uterine lavage.

Journal: NPJ precision oncology

Published: January 27, 2026

Comparative analysis of four PFAS regarding their toxicity to zebrafish development.

Comparative analysis of four PFAS regarding their toxicity to zebrafish development.

Journal: Ecotoxicology and environmental safety

Published: December 19, 2025

Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology.

Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 09, 2025

Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology.

Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 09, 2025

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Journal: JCO precision oncology

Published: September 02, 2025

Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial.

Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial.

Journal: NPJ breast cancer

Published: July 28, 2025

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

Journal: JCO precision oncology

Published: April 10, 2025

Absence of EGFR signalling in granulocytic cells relieves immunosuppression sensitising CRC metastases to immune checkpoint therapy.

Absence of EGFR signalling in granulocytic cells relieves immunosuppression sensitising CRC metastases to immune checkpoint therapy.

Journal: Cell death and differentiation

Published: April 09, 2025

The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma.

The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma.

Journal: Cancers

Published: March 31, 2025

ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34.

ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34.

Journal: Breast (Edinburgh, Scotland)

Published: January 29, 2025

Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials.

Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials.

Journal: Breast (Edinburgh, Scotland)

Published: November 14, 2024

Showing 1-12 of 159

Last Updated: 09/26/2026